How NDC Changes Impact Pharmacy Reimbursement in 2025

One of the most prevalent NDC-related reimbursement issues in 2025 involves package size mismatches between what's dispensed and what's billed. When manufacturers change package configurations-such as moving from 100-count bottles to 90-count bottles-they assign new NDC numbers. If your pharmacy management system isn't updated promptly, you may bill for the old NDC while dispensing the new package, creating quantity discrepancies that trigger claim rejections or reimbursement shortfalls.

This issue becomes particularly problematic with high-volume medications where even small per-unit reimbursement differences multiply across hundreds of prescriptions. PBMs have become increasingly sophisticated in detecting these mismatches through automated auditing systems, often resulting in retroactive claim adjustments that impact cash flow months after the original transaction. The challenge intensifies when dealing with multi-source generics where different manufacturers may have different package configurations for the same drug strength.

As pharmaceutical products are discontinued, reformulated, or repackaged, their associated NDC numbers become obsolete in payer systems, creating immediate claim rejection problems for pharmacies still holding that inventory. In 2025, the pace of NDC obsolescence has accelerated due to supply chain consolidation, manufacturer mergers, and increased FDA scrutiny of drug labeling. When you submit a claim using an obsolete NDC, payers typically reject it with codes indicating the NDC is not covered or unrecognized, forcing manual intervention to identify the correct replacement NDC and resubmit the claim.

This process delays reimbursement, increases administrative burden, and can leave you holding inventory that's difficult to bill. The challenge is compounded because different payers may retire NDC numbers at different times-an NDC that works for one insurance plan may already be obsolete in another's system.

The explosion of generic manufacturers entering the market in 2025 has created an unprecedented proliferation of NDC numbers for therapeutically equivalent products, each with potentially different Maximum Allowable Cost (MAC) pricing from PBMs. When multiple generic versions of the same drug exist, each manufacturer's product receives a unique NDC, and PBMs may reimburse these NDCs at different rates based on their own MAC pricing algorithms, preferred manufacturer relationships, or contracted rates.

This creates a complex reimbursement landscape where selecting one generic NDC over another can mean the difference between profitable and unprofitable dispensing. The challenge intensifies when your wholesaler substitutes one generic manufacturer for another without notice, potentially delivering products with NDCs that reimburse at lower rates than what you expected. Additionally, PBMs frequently update their MAC lists-sometimes weekly-meaning an NDC that reimbursed well last month may be unprofitable today.

NDC numbers exist in multiple format configurations (10-digit, 11-digit with different segment arrangements), and changes in how manufacturers, wholesalers, and payers handle these formats have created significant system compatibility challenges in 2025. The FDA's NDC Directory uses an 11-digit format with specific segment structures (5-4-2, 5-3-2, or 4-4-2), but claims processing systems, pharmacy management platforms, and payer adjudication engines may expect different formats, requiring conversion and proper zero-padding.

When NDC format conversions aren't handled correctly, claims may be rejected even though you're billing the correct product, creating frustrating technical barriers to reimbursement. This issue has intensified as more pharmacies integrate multiple technology platforms-inventory management, e-prescribing, claims processing, and analytics tools-each potentially expecting NDCs in different formats. Additionally, some payers have implemented stricter NDC format validation in 2025, rejecting claims that previously would have been accepted with format variations.

In 2025, PBMs and payers have dramatically increased scrutiny of compound medication claims, implementing new NDC reporting requirements that significantly impact reimbursement for pharmacies providing compounding services. Rather than accepting generic compound codes, many payers now require pharmacies to report specific NDCs for each ingredient used in the compound, along with precise quantities and National Council for Prescription Drug Programs (NCPDP) compound submission standards.

This granular NDC-level reporting creates substantial administrative complexity, particularly for complex compounds with multiple ingredients where each component must be accurately identified by its specific NDC, not just generic ingredient codes. Incorrect NDC reporting on compound claims can result in outright rejections, significant reimbursement reductions, or audit flags that trigger reviews of your compounding practices. Additionally, some PBMs have implemented ingredient-level MAC pricing for compounds, meaning the specific NDC you use for each ingredient directly affects your reimbursement calculation.

For covered entities participating in the 340B Drug Pricing Program, accurate NDC tracking has become critically important in 2025 as manufacturers, auditors, and regulators intensify scrutiny of split-billing practices and duplicate discount prevention. The challenge lies in maintaining precise records of which specific NDC-identified products were purchased at 340B pricing versus wholesale acquisition cost (WAC), then ensuring claims are submitted with the correct NDC and billing methodology based on patient eligibility and purchase source.

Manufacturers have become increasingly aggressive in implementing restrictions on 340B pricing for specific NDCs, particularly for products distributed through specialty pharmacies or limited distribution networks. Additionally, the Health Resources and Services Administration (HRSA) has clarified that 340B covered entities must be able to demonstrate, at the NDC level, that drugs billed as 340B were actually purchased under the program. Failure to maintain accurate NDC-level tracking can result in audit findings, manufacturer disputes, financial recoupment, and potential program exclusion.

The expanding biosimilar market in 2025 has introduced complex NDC management challenges as pharmacies navigate reimbursement for reference biologics, biosimilars, and newly designated interchangeable biosimilar products-each with distinct NDCs and potentially different payer coverage policies. Unlike small-molecule generics with straightforward substitution rules, biosimilars exist in a more nuanced regulatory and reimbursement environment where the specific NDC you dispense can dramatically impact both coverage determination and reimbursement rates.

Some payers preferentially cover specific biosimilar NDCs while excluding others, and reimbursement rates can vary significantly between therapeutically similar products. The introduction of interchangeable biosimilar designations adds another layer of complexity, as state pharmacy laws governing substitution may depend on this designation, affecting which NDC you can legally dispense against a prescription written for the reference product. Additionally, many high-cost biologics are subject to prior authorization requirements that may be NDC-specific, meaning switching between reference product and biosimilar NDCs requires new authorizations that can delay therapy.

Specialty medications, which represent a growing portion of pharmacy revenue, are particularly vulnerable to NDC-related reimbursement disruptions because they're typically subject to prior authorization requirements that are often NDC-specific. When manufacturers change specialty product NDCs due to formulation modifications, packaging changes, or supply chain adjustments, existing prior authorizations may become invalid, requiring new authorization requests that can delay therapy and jeopardize reimbursement.

In 2025, payers have implemented increasingly rigid prior authorization systems that validate not just the drug name but the specific NDC, meaning even minor NDC changes can trigger authorization denials if not properly managed. The financial stakes are substantial-specialty medications often cost thousands of dollars per prescription, meaning a single reimbursement failure due to an NDC mismatch can significantly impact monthly revenue. Additionally, some specialty medications have multiple NDC presentations (different administration devices, starter packs versus maintenance supplies) that require separate authorizations.

Direct and Indirect Remuneration (DIR) fees have become increasingly tied to specific NDC performance metrics in 2025, with PBMs calculating pharmacy quality measures and price concessions at the NDC level rather than just overall pharmacy performance. This means the specific NDCs you dispense-and how they perform against PBM-defined benchmarks for adherence, generic dispensing ratios, and cost efficiency-directly impact your DIR fee exposure and net reimbursement.

Some PBMs now apply differential DIR fees based on whether you dispensed their preferred NDC for a given therapeutic class, effectively penalizing pharmacies that select non-preferred manufacturers even when products are therapeutically equivalent. The challenge intensifies because DIR fees are typically assessed retroactively, sometimes months after the original claim, making it difficult to predict the true net reimbursement for specific NDCs at the point of sale. Additionally, as manufacturers change NDCs, historical performance data may not transfer to new codes, potentially affecting your pharmacy's quality metrics and DIR fee calculations.

Underlying all NDC-related reimbursement issues is the fundamental challenge of maintaining accurate, current NDC master file data across your pharmacy management system-a task that has become exponentially more complex in 2025 as the pace of NDC changes accelerates. Your NDC master file serves as the foundation for pricing, billing, inventory management, and clinical decision support, meaning data quality issues cascade throughout your entire operation.

Common problems include duplicate NDC records with conflicting information, outdated drug descriptions that don't match current products, incorrect package sizes that cause billing errors, missing or inaccurate therapeutic class assignments that affect formulary compliance, and broken links between NDCs and clinical databases. Many pharmacies struggle with the sheer volume of NDC updates required-manufacturers add, modify, or retire thousands of NDCs monthly, and manual update processes simply cannot keep pace. Poor NDC data quality creates a ripple effect: incorrect pricing leads to margin erosion, outdated NDCs cause claim rejections, inaccurate clinical information compromises patient safety, and unreliable inventory data affects purchasing decisions.